SOLICITATION NOTICE
Q -- Laboratory Testing Services for Serologic Markers of Pelvic Inflammatory Disease and Ovarian Cancer Risk in a Case-control Study of Ovarian Cancer Risk Conducted in Poland
- Notice Date
- 7/10/2015
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP52598-76
- Archive Date
- 7/21/2015
- Point of Contact
- Catherine Muir, Phone: (240) 276-5434
- E-Mail Address
-
muirca@mail.nih.gov
(muirca@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E144, Bethesda, MD 20892, UNITED STATES Description: National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Hormonal and Reproductive Epidemiology (HREB), plans to procure on a sole source basis the services for Luminex-based multiplex serology assay to quantify N. gonorrhoeae, and to quantify Chlamydia trachomatis, N. gonorrhoeae, HSV1, Chlamydia pneumoniae, HPV types, polyomaviruses, retroviruses, antibodies to Hepatitis B and C, Epstein Barr Virus, parvovirus, antibodies to Helicobacter pylori, Toxoplasma gondii, and cellular proteins from Deutsches Krebsforschungszentrum at the German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany. The response close date of this notice for this requirement is in accordance with FAR 5.203(a)(1). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1), and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 621511 and the business size standard is $32.5M. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price, type contract. The period of performance will not exceed twelve (12) months from date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. The Division of Cancer Epidemiology and Genetics (DCEG) is a research program of the National Cancer Institute (NCI), one of the National Institutes of Health (NIH). The Division is the world's most comprehensive cancer epidemiology research group. Its renowned epidemiologists, geneticists, and biostatisticians conduct population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The Division's research impacts public health policy in the United States and around the world. The Hormonal and Reproductive Epidemiology Branch (HREB) conducts research to identify groups at high risk of cancer, clarify the natural history of various cancers, understand the interactive effects of genetic and environmental factors on cancer risk, and elucidate biologic mechanisms of carcinogenesis. The HREB has a need to obtain results of the required tests to provide insight on of the possible relationships between gynecologic infections and ovarian cancer in serum samples from a previously conducted population-based case-control study in Poland. These tests are required to support on-going studies that are part of a comprehensive, multidisciplinary, intramural research program within the DCEG that focuses on hormonal and reproductive cancers, and other malignancies with possible hormonal etiologies (e.g., liver, esophageal). HREB's studies are on-going, and the performance characteristics and quality of the needed services are required for maintaining the integrity of these on-going studies. A change would be disruptive to the ability to analyze the cumulative results. Contractor shall perform the following tasks: • Conduct Luminex-based multiplex serology assay to quantify Neisseria gonorrhoeae in 864-samples (278-ovarian cancer cases, 556-controls, 30-blinded quality control samples) from archived specimens from the ovarian cancer case-control study in Poland. o Provide an interim report on the preliminary results two (2) weeks after initiating the analysis of serum samples. o Provide the serology quantitation data on all 864- samples in each batch, in an accessible format (such as.xlsx,.dta, or.csv). • Conduct Luminex-based multiplex serology assay to quantify antibody levels directed against Chlamydia trachomatis, N. gonorrhoeae, HSV1, Chlamydia pneumoniae, 55-HPV types, 11-polyomaviruses, 5-retroviruses, antibodies to Hepatitis B and C, Epstein Barr Virus, parvovirus, 24-antibodies to Helicobacter pylori, Toxoplasma gondii, and 4-cellular proteins in 333-samples (158-ovarian cancer cases, 158-controls, 17-blinded quality control samples) from the NCI PLCO Cancer Screening Trial. o Provide an interim report on the preliminary results two (2) weeks after initiating the analysis of serum samples. o Provide the serology quantitation data on all 864 samples run by the contractor in each batch, in an accessible format (such as.xlsx,.dta, or.csv). These laboratory testing services are provided by Deutsches Krebsforschungszentrum at the German Cancer Research Center (DKFZ). The proposed source is the only known laboratory that can perform the required tests. The laboratory at the German Cancer Research Center has developed a high throughput multiplex assay to measure antibody responses against common sexually transmitted infections and other infectious agents. No other known Vendor has an assay available that can measure antibodies directed against a large panel of infectious agents in parallel, including all infectious agents important for pelvic inflammatory disease that are relevant to the HREB's current study. While some Vendors offer assays for select targeted infectious agents, these assays do not cover all relevant agents required by the HREB. The assays are both sensitive and specific, and are imperative for the integrity and continuity of the on-going research. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 3:00PM EDT, on July 20, 2015. All responses and questions must be in writing and faxed (240) 276-5401 or emailed to Catherine Muir, Contracting Officer via electronic mail at muirca@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, Contractors must be registered and have valid, current Entity Record, including current Representations and Certifications, in the System for Award Management (SAM) through SAM.gov. Reference: N02CP52598-76 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP52598-76/listing.html)
- Record
- SN03792876-W 20150712/150710234926-155d4193583d28ed39b2ebdd285b7d30 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |